Who is this relevant for?
- Manufacturers evaluating UK market entry
- Distributors monitoring sourcing opportunities
Abbott secured FDA clearance and CE Mark for Ultreon 3.0, an AI-powered imaging platform that combines optical coherence tomography with automated insights to assist physicians during percutaneous coronary interventions (PCI). The software provides real-time plaque assessment and stent sizing guidance, aiming to improve blood flow outcomes.
Key operational features include a one-second OCT pullback with high-resolution cross-sectional views, low or zero contrast requirement, and AI-driven analysis of plaque type and vessel dimensions. This integrated workflow supports faster, more precise procedures, potentially reducing variability in complex PCI cases.
The low-contrast capability is clinically relevant for the estimated 25% of coronary artery disease patients with kidney disease. Post-procedure assessment tools verify stent expansion and flow improvement.
Abbott positions Ultreon 3.0 as a leapfrog technology that streamlines setup and reduces procedural steps. For hospitals and cath labs, adopting this platform could standardize imaging-guided PCI, reduce contrast-related complications, and improve stent selection accuracy. The dual regulatory clearances allow immediate market entry in the U.S. and Europe.